HLX43 for injection is an innovative targeted PD-L1 antibody-drug conjugate (ADC) developed in collaboration between Henlius Biotech Co., Ltd. and Suzhou Yilian Biotechnology Co., Ltd. This drug is based on a fully humanized IgG1 anti-PD-L1 monoclonal antibody, conjugated with a novel tripeptide linker and a topoisomerase I inhibitor (derived from camptothecin compounds), forming a stable … Read more
Abstract: Brain metastases (BMs) from lung cancer are one of the major factors contributing to poor prognosis in patients with non-small cell lung cancer (NSCLC). In recent years, antibody-drug conjugates (ADCs) have emerged as a new hope for treating HER2-mutant NSCLC due to their precise targeting and potent anti-tumor activity. This article focuses on the … Read more
1) The prognosis for refractory/relapsed LBCL not suitable for curative treatment is poor. The success of CD20×CD3 TCE mosunetuzumab combined with CD79b ADC polatuzumab vedotin in Phase 3 has provided patients with a novel, fixed-cycle, outpatient therapy. (Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial)In … Read more
After the announcement of the failed Phase III study HERTHENA-Lung02 of HER3 ADC at this year’s ASCO, what does it matter if you win the world? Discussing the HER3 ADC HERTHENA-lung02 study [2025 ASCO], I thought that the drug Patritumab Deruxtecan might have come to a halt. Unexpectedly, while reading literature recently, I found that … Read more
Click the arrow to follow us with the “blue text”! 1. 20ins Mutation: The ‘Hard-to-Treat Code’ of the EGFR Family The EGFR exon 20 insertion (20ins) mutation accounts for 4%-12% of NSCLC. Due to the unique mutation site, traditional EGFR-TKIs (such as gefitinib and osimertinib) struggle to bind effectively, leading to its classification as a … Read more
Click the blue text Follow us This Issue Highlights In recent years, the field of tumor immunotherapy has welcomed an important new target—DLL3. As a ligand of the Notch signaling pathway, DLL3 (Delta-like ligand 3) plays a key role in the progression of various malignant tumors, particularly in small cell lung cancer (SCLC) and neuroendocrine … Read more
Click the blue text Follow us This issue Highlights of At the 2025 WCLC, Junshi Biosciences unveiled the groundbreaking phase I clinical data of its PD-L1 ADC (HLX43), attracting widespread attention in the industry. As the next frontier in the field of immune checkpoint inhibitors, PD-L1 ADC integrates the “dual strike” mechanism of immunotherapy and … Read more
The standard treatment (SoC) for surgically resectable early-stage (I-IIIB) NSCLC patients is surgery combined with (new) adjuvant systemic therapy for patients with stage II to IIIB and certain stage IB patients, with chemotherapy and radiotherapy used in select cases (for stage III disease with mediastinal lymph node metastasis). Despite these treatments, metastatic recurrence is common … Read more
Click the blue text to follow us With the advent of biomarker-guided personalized targeted therapies and immune checkpoint inhibitors, the treatment of non-small cell lung cancer (NSCLC) continues to undergo transformation. Recently, antibody-drug conjugates (ADCs) have brought revolutionary new hope, such as trastuzumab-deruxtecan (T-DXd) being used for previously treated HER2 (ERBB2) mutated advanced NSCLC, which … Read more
Lambert-Eaton Myasthenic Syndrome (LEMS) is a disease affecting the neuromuscular junction, caused by the production of antibodies against voltage-gated calcium channels (VGCC) in the patient’s blood, leading to reduced acetylcholine release from the presynaptic membrane, resulting in specific clinical and electrophysiological manifestations. Approximately 50%-60% of LEMS patients have an associated tumor, classified as paraneoplastic syndrome … Read more